publication date: Jun. 16, 2017

Sandoz prevails over Amgen in Supreme Court case on marketing biosimilars

By Claire Dietz

Resolving a three-year-long court fight, the U.S. Supreme Court June 12 ruled that Sandoz can commence marketing of its biosimilar white blood cell growth factor immediately after getting FDA approval.

Amgen Inc., the sponsor of the reference agent, was seeking to make Sandoz wait for six-months after approval.

Sandoz is a division of the Novartis Group.

The unanimous ruling ends what insiders call the “patent dance,” a Kabuki-like process whereby two drug companies take delicate steps around each other while sorting out patent rights involved in bringing a biosimilar product to market.

“We appreciate the clarity provided on the patent dance, which will help the biosimilars industry move forward,” Carol Lynch, global head of biopharmaceuticals at Sandoz, said in a statement. “It is our responsibility to help eliminate barriers so patients can access more affordable medicine. The results of this Supreme Court case reinforce that the work we are doing every day has meaning to the patients and customers we are here to help.”

Amgen did not respond to questions from The Cancer Letter by deadline.

The case began in 2014, when Sandoz filed an application with FDA to market a biosimilar filgrastim called Zarxio, with Amgen’s Neupogen, as the reference product.

Amgen holds patents on the methods of manufacturing and using filgrastim, the … Continue reading Sandoz prevails over Amgen in Supreme Court case on marketing biosimilars

To access this members-only content, please log in.
If you're not a subscriber why not join today?
If you believe you should be able to view this area but cannot log in, then please contact us and we will try to rectify this issue as soon as possible.
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2017 The Cancer Letter Inc.